Literature DB >> 2755700

Autocrine interaction between TGF alpha and the EGF-receptor: quantitative requirements for induction of the malignant phenotype.

E Di Marco1, J H Pierce, T P Fleming, M H Kraus, C J Molloy, S A Aaronson, P P Di Fiore.   

Abstract

Alterations affecting the epidermal growth factor (EGF)/transforming growth factor alpha (TGF alpha)-responsive mitogenic pathway are frequently detected in malignancies. In particular, the EGF-receptor (EGFR) molecule has been found overexpressed in a number of human tumors, and TGF alpha is produced by a large array of tumor cells. Gene transfer experiments have previously demonstrated that expression of either TGF alpha or EGFR alone is not sufficient to induce the transformed phenotype in NIH3T3 cells. In this study we sought to investigate the biological effect of expression of TGF alpha and high levels of EGFR in this model system. We demonstrate that the gene for TGF alpha acts as a potent oncogene in NIH3T3 cells overexpressing EGFR (NIH-EGFR, greater than 10(6) EGFR). We further show that TGF alpha directly stimulates proliferation of the cell in which it is produced and provide evidence that the extracellular compartment of the transformed cell is the major site of interaction between TGF alpha and EGFR. Analysis of human tumor cell lines revealed a strong correlation between expression of TGF alpha and overexpression of EGFR. Moreover, high levels of EGF-independent tyrosine phosphorylation of the EGFR were detected both in NIH-EGFR expressing TGF alpha and in high EGFR and TGF alpha coexpressing human tumor cell lines. Thus, the two events instituting the EGFR/TGF alpha autocrine loop responsible for transformation in vitro may play a role in the development of some human malignancies.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2755700

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  61 in total

1.  TGF-alpha exerts biphasic effects on estrogen--and phytoestrogen-mediated gene expression in breast cancer cells.

Authors:  S T Willard; L S Frawley
Journal:  Endocrine       Date:  1999-08       Impact factor: 3.633

2.  Correlation between the Concentration of c-erbB-2 Protein, EGF-receptor and TGF alpha in Breast Cancer Tissue, and Clinicopathological Parameters.

Authors: 
Journal:  Breast Cancer       Date:  1994-07-30       Impact factor: 4.239

3.  Matrix-independent survival of human keratinocytes through an EGF receptor/MAPK-kinase-dependent pathway.

Authors:  M Jost; T M Huggett; C Kari; U Rodeck
Journal:  Mol Biol Cell       Date:  2001-05       Impact factor: 4.138

Review 4.  Monoclonal antibodies to epidermal growth factor receptors in studies of receptor structure and function.

Authors:  T Kawamoto; G H Sato; K Takahashi; M Nishi; S Taniguchi; J D Sato
Journal:  Cytotechnology       Date:  1990-05       Impact factor: 2.058

5.  Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.

Authors:  M Alimandi; L M Wang; D Bottaro; C C Lee; A Kuo; M Frankel; P Fedi; C Tang; M Lippman; J H Pierce
Journal:  EMBO J       Date:  1997-09-15       Impact factor: 11.598

6.  Epidermal growth factor and transforming growth factor-alpha: differential intracellular routing and processing of ligand-receptor complexes.

Authors:  R Ebner; R Derynck
Journal:  Cell Regul       Date:  1991-08

7.  The N-terminal propiece of interleukin 1 alpha is a transforming nuclear oncoprotein.

Authors:  F T Stevenson; J Turck; R M Locksley; D H Lovett
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

Review 8.  Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants.

Authors:  Byung Min Chung; Eric Tom; Neha Zutshi; Timothy Alan Bielecki; Vimla Band; Hamid Band
Journal:  World J Clin Oncol       Date:  2014-12-10

9.  Expression of growth factors and their receptors in human esophageal carcinomas: regulation of expression by epidermal growth factor and transforming growth factor alpha.

Authors:  K Yoshida; H Kuniyasu; W Yasui; Y Kitadai; T Toge; E Tahara
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

10.  Targeting HER2 in breast cancer: overview of long-term experience.

Authors:  Evan Lantz; Ivan Cunningham; Gerald M Higa
Journal:  Int J Womens Health       Date:  2010-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.